Download PDF
Thromb Haemost 2009; 102(02): 404-411
DOI: 10.1160/TH09-02-0126
New Technologies, Diagnostic Tools and Drugs
Schattauer GmbH

Response to aspirin in healthy individuals

Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B2
Normand Blais
1   Hematology and blood bank department, CHUM, Hôpital Notre Dame, Montréal, Québec, Canada
3   Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada
,
Chantal Pharand
2   Faculty of Pharmacy, Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada
4   Research Center, Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada
5   Department of Pharmacy, Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada
,
Marie Lordkipanidzé
2   Faculty of Pharmacy, Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada
4   Research Center, Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada
5   Department of Pharmacy, Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada
,
Ying K. Sia
4   Research Center, Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada
,
Yahye Merhi
7   Montreal Heart Institute Research Center, Montréal, Québec, Canada
,
Jean G. Diodati
3   Faculty of Medicine, Université de Montréal, Montréal, Québec, Canada
4   Research Center, Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada
6   Division of Cardiology, Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada
› Author AffiliationsFinancial support: This study was made possible through a grant from the Fondation de l’Hôpital du Sacré-Coeur de Montréal, Montréal, Canada. Normand Blais and Marie Lordkipanidzé are recipients of Training Awards from the Fonds de recherche en santé du Québec.
Further Information

Publication History

Received: 25 February 2009

Accepted after minor revision: 26 March 2009

Publication Date:
22 November 2017 (online)

    Permissions and Reprints

Summary

Variable biological effect of aspirin is suggested to be related to pharmacological resistance. The incidence of this so-called “resistant” state varies with the study population and the assay used. We determined performance features of five assays used to assess aspirin effects in non-smoking healthy volunteers not taking any drug known to interfere with platelet function. Blood and urine samples were obtained immediately before and after 8–10 days of aspirin 80 mg intake. Forty-five participants 19–59 years old were enrolled. The sensitivity (SE), specificity (SP), and optimal cut-off (CO) value to detect the effect of aspirin were: light transmission aggregometry (LTA) with 1.6 mM arachidonic acid (AA) – SE 100%,SP 95.9%,CO 20%;LTA with adenosine diphosphate (ADP) 10 µM – SE 84.4%, SP 77.8%, CO 70%; Ver-

Keywords

Agregometry - aspirin - thromboelastography - thromboxane - VerifyNow

* Institution where work was carried out: Hôpital du Sacré-Cœur de Montréal, Montréal, Québec, Canada


 

  • References

  • 1 Snoep JD, Hovens MM, Eikenboom JC. et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-1599.
    CrossrefPubMedGoogle Scholar
  • 2 Eikelboom JW, Hirsh J, Weitz JI. et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655.
    CrossrefPubMedGoogle Scholar
  • 3 Gum PA, Kottke-Marchant K, Poggio ED. et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-235.
    CrossrefPubMedGoogle Scholar
  • 4 Pulcinelli FM, Pignatelli P, Celestini A. et al. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 2004; 43: 979-984.
    CrossrefPubMedGoogle Scholar
  • 5 Wang JC, Aucoin-Barry D, Manuelian D. et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 2003; 92: 1492-1494.
    CrossrefPubMedGoogle Scholar
  • 6 Zimmermann N, Hohlfeld T. Clinical implications of aspirin resistance. Thromb Haemost 2008; 100: 379-390.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Chen WH, Lee PY, Ng W. et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43: 1122-1126.
    CrossrefPubMedGoogle Scholar
  • 8 Becker DM, Segal J, Vaidya D. et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. J Am Med Assoc 2006; 295: 1420-1427.
    CrossrefPubMedGoogle Scholar
  • 9 Davis JW, Hartman CR, Lewis Jr. HD. et al. Cigarette smoking--induced enhancement of platelet function: lack of prevention by aspirin in men with coronary artery disease. J Lab Clin Med 1985; 105: 479-483.
    PubMedGoogle Scholar
  • 10 Hung J, Lam JYT, Lacoste L. et al. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995; 92: 2432-2436.
    CrossrefPubMedGoogle Scholar
  • 11 Gulmez O, Yildirir A, Bal U. et al. Assessment of biochemical aspirin resistance at rest and immediately after exercise testing. Blood Coagul Fibrinolysis 2007; 18: 9-13.
    CrossrefPubMedGoogle Scholar
  • 12 Watala C, Golanski J, Pluta J. et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)--its relation to metabolic control. Thromb Res 2004; 113: 101-113.
    CrossrefPubMedGoogle Scholar
  • 13 Friend M, Vucenik I, Miller M. Research pointers: Platelet responsiveness to aspirin in patients with hyperlipidaemia. Br Med J 2003; 326: 82-83.
    CrossrefPubMedGoogle Scholar
  • 14 Szczeklik A, Musial J, Undas A. et al. Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1996; 16: 948-954.
    CrossrefPubMedGoogle Scholar
  • 15 Zimmermann N, Wenk A, Kim U. et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108: 542-547.
    CrossrefPubMedGoogle Scholar
  • 16 Fontana P, Nolli S, Reber G. et al. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost 2006; 04: 813-819.
    CrossrefPubMedGoogle Scholar
  • 17 Frelinger AL, Li Y, Linden MD. et al. Aspirin ‘resistance’: role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost 2008; 06: 2035-2044.
    CrossrefPubMedGoogle Scholar
  • 18 Madsen EH, Schmidt EB, Maurer-Spurej E. et al. Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100. Platelets 2008; 19: 335-341.
    CrossrefPubMedGoogle Scholar
  • 19 Faraday N, Becker DM, Yanek LR. et al. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am J Cardiol 2006; 98: 774-779.
    CrossrefPubMedGoogle Scholar
  • 20 Feher G, Feher A, Pusch G. et al. The genetics of antiplatelet drug resistance. Clin Genet 2009; 75: 1-18.
    CrossrefPubMedGoogle Scholar
  • 21 Burke J, Kraft WK, Greenberg HE. et al. Relationship of arachidonic acid concentration to cyclooxygenase-dependent human platelet aggregation. J Clin Pharmacol 2003; 43: 983-989.
    CrossrefPubMedGoogle Scholar
  • 22 Gum PA, Kottke-Marchant K, Welsh PA. et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965.
    CrossrefPubMedGoogle Scholar
  • 23 Lordkipanidze M, Pharand C, Schampaert E. et al. Evaluation of the platelet count drop method for assessment of platelet function in comparison with “gold standard” light transmission aggregometry. Thromb Res. 2009 epub ahead of print..
    PubMedGoogle Scholar
  • 24 Harrison P. Advances in platelet counting. Br J Haematol 2000; 111: 733-744.
    PubMedGoogle Scholar
  • 25 Nicholson N, Panzer-Knodle S, Haas N. et al. Assessment of platelet function assays. Am Heart J 1998; 135: S170-S178.
    CrossrefPubMedGoogle Scholar
  • 26 Bochsen L, Wiinberg B, Kjelgaard-Hansen M. et al. Evaluation of the TEG platelet mapping assay in blood donors. Thromb J 2007; 05: 3.
    CrossrefPubMedGoogle Scholar
  • 27 Rivard G, Cohen E, Hofer A. et al. The use of thrombelastograph to monitor the aspirin induced inhibition of platelet response to arachidonic acid. Blood 2003; 102: 65b.
    PubMedGoogle Scholar
  • 28 Catella F, Healy D, Lawson JA. et al. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci USA 1986; 83: 5861-5865.
    CrossrefPubMedGoogle Scholar
  • 29 Awtry EH, Loscalzo J. Aspirin. Circulation 2000; 101: 1206-1218.
    CrossrefPubMedGoogle Scholar
  • 30 Solberg H. The theory of reference values. Part 5. Statistical treatment of collected reference values. Determination of reference limits. J Clin Chem Clin Biochem 1987; 25: 645-656.
    PubMedGoogle Scholar
  • 31 NCCLS. How to Define and Determine Reference Intervals in the Clinical Laboratory; Approved Guideline---Second Edition. NCCLS document C28-A2. NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087 USA. 2000
    PubMedGoogle Scholar
  • 32 Lordkipanidze M, Pharand C, Schampaert E. et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28: 1702-1708.
    CrossrefPubMedGoogle Scholar
  • 33 Dyszkiewicz-Korpanty AM, Kim A, Burner JD. et al. Comparison of a rapid platelet function assay - Verify Nowtrade mark Aspirin - with whole blood impedance aggregometry for the detection of aspirin resistance. Thromb Res 2007; 120: 485-488.
    CrossrefPubMedGoogle Scholar
  • 34 Santos MT, Valles J, Lago A. et al. Residual platelet thromboxane A2 and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease. J Thromb Haemost 2008; 06: 615-621.
    CrossrefPubMedGoogle Scholar
  • 35 Lennon MJ, Gibbs NM, Weightman WM. et al. A comparison of Plateletworks and platelet aggregometry for the assessment of aspirin-related platelet dysfunction in cardiac surgical patients. J Cardiothorac Vasc Anesth 2004; 18: 136-140.
    CrossrefPubMedGoogle Scholar
  • 36 Dichiara J, Bliden KP, Tantry US. et al. Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients. Platelets 2007; 18: 414-423.
    CrossrefPubMedGoogle Scholar
  • 37 Helena Laboratories. Point Of Care. Helena Plateletworks. Plateletworks Arachidonic Acid Procedure, Pro 119 Rev 3. Available at: http://www.helena.com/ Procedures/Pro119Rev3.pdf Accessed March 21,2009
    PubMedGoogle Scholar
  • 38 Mayne E, Jacobson B, Louw S. et al. The utility of thrombo-elastography in the monitoring of aspirin therapy. S Afr Med J 2007; 97: 1289-1291.
    PubMedGoogle Scholar
  • 39 Hobson AR, Petley GW, Dawkins KD. et al. A novel fifteen minute test for assessment of individual timedependent clotting responses to aspirin and clopidogrel using modified thrombelastography. Platelets 2007; 18: 497-505.
    CrossrefPubMedGoogle Scholar
  • 40 Berger JS, Roncaglioni MC, Avanzini F. et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. J Am Med Assoc 2006; 295: 306-313.
    CrossrefPubMedGoogle Scholar
  • 41 Krasopoulos G, Brister SJ, Beattie WS. et al. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 2008; 336: 195-198.
    CrossrefPubMedGoogle Scholar
  • 42 Reny JL, de Moerloose P, Dauzat M. et al. Use of the PFA-100trade mark closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008; 06: 444-450.
    CrossrefPubMedGoogle Scholar
  • 43 Guthikonda S, Mangalpally K, Vaduganathan M. et al. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy. Thromb Haemost 2008; 100: 83-89.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Gori AM, Marcucci R, Paniccia R. et al. Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function. Thromb Haemost 2008; 100: 1136-1145.
    Article in Thieme ConnectPubMedGoogle Scholar